Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CLL1 + CD33 + ADGRE2 CAR-T
- Development stage
- Unknown
- Lead developer
- Zhejiang University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
CLL1 + CD33 + ADGRE2 CAR-T is an experimental trivalent chimeric antigen receptor (CAR) T-cell therapy developed by The First Affiliated Hospital of Medical College of Zhejiang University for the treatment of relapsed or refractory acute myeloid leukemia (AML). This cell therapy is engineered to simultaneously target three distinct antigens highly expressed on AML blasts and leukemic stem cells: C-type lectin-like molecule-1 (CLL-1/CLEC12A), CD33, and Adhesion G protein-coupled receptor E2 (ADGRE2). By targeting multiple antigens, the therapy aims to overcome the significant clonal heterogeneity characteristic of AML and prevent disease relapse caused by antigen escape, a common limitation of single-target CAR-T therapies. The product is currently being evaluated in early-phase clinical trials to assess its safety and preliminary efficacy in patients who have failed standard induction therapies.
- Other names
- CLL1-CD33-ADGRE2 CAR-TCLL-1-CD33-ADGRE2 CAR-TCLL 1-CD33-ADGRE2 CAR-TTrivalent AML CAR-T
02
Targets
CLEC12AADGRE2 (Adhesion G protein-coupled receptor E2)CD33 (Myeloid cell surface antigen CD33)
Beyond the preview
Go deeper on CLL1 + CD33 + ADGRE2 CAR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CLL1 + CD33 + ADGRE2 CAR-T.